{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Renal+Cell+Cancer+AJCC+v7", "query": { "condition": "Stage III Renal Cell Cancer AJCC v7" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 145, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Renal+Cell+Cancer+AJCC+v7&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:14:28.652Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005966", "title": "Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-02-05", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • South Bend, Indiana • Des Moines, Iowa + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005966" }, { "nct_id": "NCT00403169", "title": "Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 26, "start_date": "2004-08", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403169" }, { "nct_id": "NCT01120249", "title": "S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1545, "start_date": "2011-04-01", "completion_date": "2025-09-01", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1002, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120249" }, { "nct_id": "NCT04981509", "title": "Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Leiomyomatosis and Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Renal Cell Carcinoma", "Sporadic Papillary Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sodium Fluoride F-18", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 65, "start_date": "2022-06-10", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 13, "location_summary": "La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981509" }, { "nct_id": "NCT02721732", "title": "Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Carcinoma of Unknown Primary", "Metastatic Adrenal Gland Pheochromocytoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Germ Cell Tumor", "Metastatic Malignant Solid Neoplasm", "Metastatic Paraganglioma", "Metastatic Penile Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Small Cell Carcinoma", "Stage III Adrenal Cortex Carcinoma AJCC v7", "Stage IV Adrenal Cortex Carcinoma AJCC v7", "Stage IV Penile Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Unresectable Adrenal Gland Pheochromocytoma", "Unresectable Paraganglioma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Solid Neoplasm", "Vascular Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2016-08-15", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02721732" }, { "nct_id": "NCT04393350", "title": "Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2020-06-22", "completion_date": "2026-12-11", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04393350" }, { "nct_id": "NCT01846520", "title": "Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Subject", "Localized Transitional Cell Cancer of the Renal Pelvis and Ureter", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Psychosocial Effects of Cancer and Its Treatment", "Recurrent Bladder Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Gastric Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Uterine Sarcoma", "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter", "Stage II Bladder Cancer", "Stage II Renal Cell Cancer", "Stage II Urethral Cancer", "Stage IIA Cervical Cancer", "Stage IIA Colon Cancer", "Stage IIA Gastric Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIA Pancreatic Cancer", "Stage IIA Rectal Cancer", "Stage IIA Uterine Sarcoma", "Stage IIB Cervical Cancer", "Stage IIB Colon Cancer", "Stage IIB Gastric Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIB Pancreatic Cancer", "Stage IIB Rectal Cancer", "Stage IIB Uterine Sarcoma", "Stage IIC Colon Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage IIC Rectal Cancer", "Stage III Bladder Cancer", "Stage III Pancreatic Cancer", "Stage III Renal Cell Cancer", "Stage III Urethral Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Gastric Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Rectal Cancer", "Stage IIIA Uterine Sarcoma", "Stage IIIB Cervical Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Gastric Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Rectal Cancer", "Stage IIIB Uterine Sarcoma", "Stage IIIC Colon Cancer", "Stage IIIC Gastric Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Rectal Cancer", "Stage IIIC Uterine Sarcoma", "Stage IV Bladder Cancer", "Stage IV Gastric Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IV Urethral Cancer", "Stage IVA Cervical Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Uterine Sarcoma", "Stage IVB Cervical Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Stage IVB Uterine Sarcoma", "Ureter Cancer", "Stage IIA Lung Carcinoma", "Stage IIB Lung Carcinoma", "Stage IIIA Lung Carcinoma", "Stage IIIB Lung Carcinoma" ], "interventions": [ { "name": "educational intervention", "type": "OTHER" }, { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2013-10", "completion_date": "2019-05-23", "has_results": false, "last_update_posted_date": "2020-01-23", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01846520" }, { "nct_id": "NCT06349642", "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Triple-Negative Breast Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Skin Neoplasm", "Metastatic Malignant Solid Neoplasm", "Resectable Lung Non-Small Cell Carcinoma", "Early Stage Lung Non-Small Cell Carcinoma", "Resectable Malignant Solid Neoplasm", "Resectable Triple-Negative Breast Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Recurrent Cervical Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Tissue Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2024-04-24", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06349642" }, { "nct_id": "NCT00499733", "title": "Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Cryoablation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2013-01-09", "has_results": false, "last_update_posted_date": "2019-01-18", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499733" }, { "nct_id": "NCT06049576", "title": "Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Myrciaria dubia Prebiotic Supplement", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-10-06", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-22T04:14:28.652Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06049576" } ] }